Evidence map›Paper›PMID 33525493›Full record

ArticleCells2021

Unexpected Pro-Fibrotic Effect of MIF in Non-Alcoholic Steatohepatitis Is Linked to a Shift in NKT Cell Populations.

Daniel Heinrichs, Elisa F Brandt, Petra Fischer, Janine Köhncke, Theresa H Wirtz, Nurdan Guldiken, Sonja Djudjaj, Peter Boor, Daniela Kroy, Ralf Weiskirchen and 6 more

Abstract read
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Daniel HeinrichsDepartment of Internal Medicine III, RWTH Aachen University, 52074 Aachen, Germany.
Elisa F BrandtDepartment of Internal Medicine III, RWTH Aachen University, 52074 Aachen, Germany.
Petra FischerDepartment of Internal Medicine III, RWTH Aachen University, 52074 Aachen, Germany.
Janine KöhnckeDepartment of Internal Medicine III, RWTH Aachen University, 52074 Aachen, Germany.
Theresa H WirtzDepartment of Internal Medicine III, RWTH Aachen University, 52074 Aachen, Germany.
Nurdan GuldikenDepartment of Internal Medicine III, RWTH Aachen University, 52074 Aachen, Germany.ORCID 0000-0001-7966-6777
Sonja DjudjajInstitute of Pathology, RWTH Aachen University, 52074 Aachen, Germany.
Peter BoorInstitute of Pathology, RWTH Aachen University, 52074 Aachen, Germany.
Daniela KroyDepartment of Internal Medicine III, RWTH Aachen University, 52074 Aachen, Germany.
Ralf WeiskirchenInstitute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry, RWTH University Hospital Aachen, 52074 Aachen, Germany.ORCID 0000-0003-3888-0931
Richard BucalaRheumatology Section of the Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520-8031, USA.
Hermann E WasmuthDepartment of Internal Medicine III, RWTH Aachen University, 52074 Aachen, Germany.
Pavel StrnadDepartment of Internal Medicine III, RWTH Aachen University, 52074 Aachen, Germany.ORCID 0000-0002-7122-6379
Christian TrautweinDepartment of Internal Medicine III, RWTH Aachen University, 52074 Aachen, Germany.
Jürgen BernhagenChair of Vascular Biology, Institute of Stroke and Dementia Research, LMU Klinikum, Lud-wig-Maximilian-University (LMU), 81377 Munich, Germany.ORCID 0000-0003-2996-2652
Marie-Luise BerresDepartment of Internal Medicine III, RWTH Aachen University, 52074 Aachen, Germany.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Bundesministerium für Bildung und Forschung 031L0041Deutsche Forschungsgemeinschaft 36842431Deutsche Forschungsgemeinschaft EXC1010NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

Macrophage migration inhibitory factor (MIF) is a pleiotropic inflammatory cytokine with anti-fibrotic properties in toxic liver injury models and anti-steatotic functions in non-alcoholic fatty liver disease (NAFLD) attributed to the CD74/AMPK signaling pathway. As NAFLD progression is associated with fibrosis, we studied MIF function during NAFLD-associated liver fibrogenesis in mice and men by molecular, histological and immunological methods in vitro and in vivo. After NASH diet feeding, hepatic

Indexed as

AnimalsBiomarkersCell PolarityDietDisease ProgressionFibrosisGene Expression RegulationHepatic Stellate CellsHepatocytesHumansLiverMacrophage Migration-Inhibitory FactorsMaleMiceMice, Inbred C57BLModels, BiologicalBiomarkersmacrophage migration inhibitory factor receptorMacrophage Migration-Inhibitory FactorsReceptors, Immunologicliver fibrosisMIFNASHNKT cells

Identifiers

PMID33525493
PMCPMC7918903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.